Host |
Rabbit |
Klon |
SP130 |
Format |
Concentrate |
Methode |
P, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to an internal region of human Ku80 protein |
Lokalisation |
Nucleus |
Ku80
|
Zytomed Systems GmbH |
SP130 |
0.5 ml |
Concentrate |
RUO |
511-4302 |
-
|
Host |
Rabbit |
Klon |
SP130 |
Format |
Concentrate |
Methode |
P, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to an internal region of human Ku80 protein |
Lokalisation |
Nucleus |
Ku80
|
Zytomed Systems GmbH |
SP130 |
1 ml |
Concentrate |
RUO |
511-4304 |
-
|
Host |
Mouse+Rabbit |
Klon |
L26+SP7 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
IgG2a+IgG |
Lokalisation |
Cell membrane |
L26 + CD3
|
Biocare Medical |
L26+SP7 |
6 ml |
Ready-to-use |
CE/IVD |
PM237DSAA |
-
|
Host |
Rabbit |
Klon |
CAL26 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG1 |
Lokalisation |
Cell membrane and cytoplasm |
LAG3
|
Biocare Medical |
CAL26 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3213A |
-
|
Host |
Rabbit |
Klon |
CAL26 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG1 |
Lokalisation |
Cell membrane and cytoplasm |
LAG3
|
Biocare Medical |
CAL26 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3213B |
-
|
Host |
Rabbit |
Klon |
CAL26 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Rabbit IgG1 |
Lokalisation |
Cell membrane and cytoplasm |
LAG3
|
Biocare Medical |
CAL26 |
6 ml |
Ready-to-use |
CE/IVD |
API3213AA |
-
|
Host |
Mouse |
Klon |
LcN-2 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Purified human IgG |
Lokalisation |
Cytoplasm |
Lambda
|
Zeta Corporation |
LcN-2 |
1.0 ml |
Concentrate |
CE/IVD |
Z2457ML |
-
|
Host |
Mouse |
Klon |
LcN-2 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil. |
Verdünnung |
- |
Isotyp |
IgG2a /κ |
Verdünnung |
Purified human IgG |
Lokalisation |
Cytoplasm |
Lambda
|
Zeta Corporation |
LcN-2 |
7 ml |
Ready-to-use |
CE/IVD |
Z2457MP |
-
|
Host |
Mouse |
Klon |
LcN-2 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Purified human IgG |
Lokalisation |
Cytoplasm |
Lambda
|
Zeta Corporation |
LcN-2 |
0.5 ml |
Concentrate |
CE/IVD |
Z2457MS |
-
|
Host |
Mouse |
Klon |
LcN-2 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Purified human IgG |
Lokalisation |
Cytoplasm |
Lambda
|
Zeta Corporation |
LcN-2 |
0.1 ml |
Concentrate |
CE/IVD |
Z2457MT |
-
|
Host |
Mouse |
Klon |
N10/2 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Reveal modified citrate buffer pH 6.0 |
Positivkontrolle |
Tonsil or bone marrow |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Lambda Light Chain
|
Biocare Medical |
N10/2 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3063A |
-
|
Host |
Mouse |
Klon |
N10/2 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Reveal modified citrate buffer pH 6.0 |
Positivkontrolle |
Tonsil or bone marrow |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Lambda Light Chain
|
Biocare Medical |
N10/2 |
1 ml |
Concentrate |
CE/IVD |
ACI3063C |
-
|
Host |
Mouse |
Klon |
N10/2 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Reveal modified citrate buffer pH 6.0 |
Positivkontrolle |
Tonsil or bone marrow |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Lambda Light Chain
|
Biocare Medical |
N10/2 |
6 ml |
Ready-to-use |
CE/IVD |
API3063AA |
-
|
Host |
Mouse |
Klon |
N10/2 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 - 1:200 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cytoplasm |
Lambda Light Chain
|
Diagnostic Biosystems |
N10/2 |
1 ml |
Concentrate |
CE/IVD |
MOB077 |
-
|
Host |
Mouse |
Klon |
N10/2 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 - 1:200 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cytoplasm |
Lambda Light Chain
|
Diagnostic Biosystems |
N10/2 |
0.1 ml |
Concentrate |
CE/IVD |
MOB077-01 |
-
|
Host |
Mouse |
Klon |
N10/2 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 - 1:200 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cytoplasm |
Lambda Light Chain
|
Diagnostic Biosystems |
N10/2 |
0.5 ml |
Concentrate |
CE/IVD |
MOB077-05 |
-
|
Host |
Mouse |
Klon |
N10/2 |
Format |
Ready-to-use |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cytoplasm |
Lambda Light Chain
|
Diagnostic Biosystems |
N10/2 |
6 ml |
Ready-to-use |
CE/IVD |
PDM056 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Verdünnung |
1:20 - 1:40 |
Isotyp |
Rabbit Ig |
Lambda Light Chain FITC
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
F002 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Verdünnung |
1:20 - 1:40 |
Isotyp |
Rabbit Ig |
Lambda Light Chain FITC
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
F002-01 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Serum |
Methode |
F, P, EL |
Positivkontrolle |
Human Kidney |
Isotyp |
Rabbit IgG |
Verdünnung |
Purified laminin from Engelbreth-Holm-Swan (EHS) |
Laminin
|
Zytomed Systems GmbH |
polyclonal |
0.25 ml |
Serum |
RUO |
612-0052 |
-
|
Host |
Mouse |
Klon |
4C7 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Pepsin |
Positivkontrolle |
Skin |
Verdünnung |
1:5 - 1:20 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Basement Membrane |
Laminin
|
Diagnostic Biosystems |
4C7 |
1 ml |
Concentrate |
CE/IVD |
MOB202 |
-
|
Host |
Mouse |
Klon |
4C7 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Pepsin |
Positivkontrolle |
Skin |
Verdünnung |
1:5 - 1:20 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Basement Membrane |
Laminin
|
Diagnostic Biosystems |
4C7 |
0.1 ml |
Concentrate |
CE/IVD |
MOB202-01 |
-
|
Host |
Mouse |
Klon |
4C7 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Pepsin |
Positivkontrolle |
Skin |
Verdünnung |
1:5 - 1:20 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Basement Membrane |
Laminin
|
Diagnostic Biosystems |
4C7 |
0.5 ml |
Concentrate |
CE/IVD |
MOB202-05 |
-
|
Host |
Mouse |
Klon |
4C7 |
Format |
ready-to-use |
Methode |
F, P |
Vorbehandlung |
Pepsin |
Positivkontrolle |
Skin |
Verdünnung |
- |
Isotyp |
Mouse IgG2a |
Lokalisation |
Basement Membrane |
Laminin
|
Diagnostic Biosystems |
4C7 |
6 ml |
ready-to-use |
CE/IVD |
PDM568 |
-
|
Host |
Mouse |
Klon |
450-30A |
Format |
Purified |
Methode |
F, FL |
Isotyp |
Mouse IgG1 |
Verdünnung |
Alpha 6 beta 4 integrin purified from A431 cells |
Laminin Receptor (CD49f, Integrin alpha6)
|
Zytomed Systems GmbH |
450-30A |
100 µg |
Purified |
RUO |
612-0058 |
-
|
Host |
Rat |
Klon |
NKI-GoH3 |
Format |
Purified |
Methode |
F, IP, FL |
Isotyp |
Rat IgG2a |
Verdünnung |
BALB/c mouse mammary tumour cells |
Laminin Receptor (CD49f, Integrin alpha6)
|
Zytomed Systems GmbH |
NKI-GoH3 |
100 µg |
Purified |
RUO |
612-0061 |
-
|
Host |
Rabbit |
Klon |
ZR170 |
Format |
concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
skin/Langerhans cell histiocytosis |
Verdünnung |
1:100-200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment (around aa50-250) of human Langerin protein |
Lokalisation |
Cell Surface and cytoplasmic |
Langerin
|
Zeta Corporation |
ZR170 |
0.5 ml |
concentrate |
RUO |
Z2700RS-R |
-
|
Host |
Rabbit |
Klon |
ZR336 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Chronic lymphocytic leukemia or small lymphocytic lymphoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Fragment (around aa 100-200) of human LEF1 protein |
Lokalisation |
Nucleus |
LEF1
|
Zeta Corporation |
ZR336 |
1 ml |
Concentrate |
CE/IVD |
Z2642RL |
-
|
Host |
Rabbit |
Klon |
ZR336 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Chronic lymphocytic leukemia or small lymphocytic lymphoma |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Fragment (around aa 100-200) of human LEF1 protein |
Lokalisation |
Nucleus |
LEF1
|
Zeta Corporation |
ZR336 |
7 ml |
Ready-to-use |
CE/IVD |
Z2642RP |
-
|
Host |
Rabbit |
Klon |
ZR336 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Chronic lymphocytic leukemia or small lymphocytic lymphoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Fragment (around aa 100-200) of human LEF1 protein |
Lokalisation |
Nucleus |
LEF1
|
Zeta Corporation |
ZR336 |
0.5 ml |
Concentrate |
CE/IVD |
Z2642RS |
-
|
Host |
Rabbit |
Klon |
ZR336 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Chronic lymphocytic leukemia or small lymphocytic lymphoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Fragment (around aa 100-200) of human LEF1 protein |
Lokalisation |
Nucleus |
LEF1
|
Zeta Corporation |
ZR336 |
0.1 ml |
Concentrate |
CE/IVD |
Z2642RT |
-
|
Host |
Mouse |
Klon |
CA7AE |
Format |
Lyophilised |
Methode |
IF, EL, WB |
Isotyp |
Mouse IgM |
Verdünnung |
Heat killed L. donovani promastigotes |
Leishmania (LPG Repeat Epitope)
|
Zytomed Systems GmbH |
CA7AE |
0.5 ml |
Lyophilised |
RUO |
612-0093 |
-
|
Host |
Mouse |
Klon |
96/26 |
Format |
Lyophilised |
Methode |
IF, EL |
Isotyp |
Mouse IgG2a |
Verdünnung |
Recombinant Baculovirus expressed L. major p63 |
Leishmania (Major Surface Protease GP-63)
|
Zytomed Systems GmbH |
96/26 |
0.5 ml |
Lyophilised |
RUO |
612-0094 |
-
|
Host |
Goat |
Klon |
polyclonal |
Format |
Purified |
Methode |
EL, WB |
Isotyp |
Goat IgG |
Verdünnung |
Peptide sequence C-TQDDIEKHQSDAG from the internal region of leptin receptor (NP-002294.2, NP-001003679.1, NP-001003680.1) |
Leptin Receptor
|
Zytomed Systems GmbH |
polyclonal |
100 µg |
Purified |
RUO |
612-0191 |
-
|
Host |
Rabbit |
Klon |
ZR173 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Pituitary |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant full-length human LHB protein |
Lokalisation |
Cytoplasm, secreted |
LH
|
Zeta Corporation |
ZR173 |
1 ml |
Concentrate |
CE/IVD |
Z2701RL |
-
|
Host |
Rabbit |
Klon |
ZR173 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Pituitary |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Recombinant full-length human LHB protein |
Lokalisation |
Cytoplasm, secreted |
LH
|
Zeta Corporation |
ZR173 |
7 ml |
Concentrate |
CE/IVD |
Z2701RP |
-
|
Host |
Rabbit |
Klon |
ZR173 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Pituitary |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant full-length human LHB protein |
Lokalisation |
Cytoplasm, secreted |
LH
|
Zeta Corporation |
ZR173 |
0.5 ml |
Concentrate |
CE/IVD |
Z2701RS |
-
|
Host |
Rabbit |
Klon |
ZR173 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Pituitary |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant full-length human LHB protein |
Lokalisation |
Cytoplasm, secreted |
LH
|
Zeta Corporation |
ZR173 |
0.1 ml |
Concentrate |
CE/IVD |
Z2701RT |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Reaktivität |
BV, CK, DG, FG, MS, PG, RB, RT |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Hodgkin´s Lymphoma, tonsil |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to human LMO2 protein |
Lokalisation |
Nucleus |
LMO2
|
Zytomed Systems GmbH |
polyclonal |
0.5 ml |
Concentrate |
RUO |
512-17832 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Reaktivität |
BV, CK, DG, FG, MS, PG, RB, RT |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Hodgkin´s Lymphoma, tonsil |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to human LMO2 protein |
Lokalisation |
Nucleus |
LMO2
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
512-17834 |
-
|
Host |
Rabbit |
Klon |
SP51 |
Reaktivität |
BV,CK,DG,PG,RB,RT |
Methode |
IHC-P, WB, FC |
Vorbehandlung |
Citrate |
Verdünnung |
1:100 |
LMO2
|
Zytomed Systems GmbH |
SP51 |
1 ml |
- |
RUO |
512-3514 |
-
|
Host |
Rabbit |
Klon |
ZR87 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Lymph Node |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant human LMO2 protein fragment (around aa 23-140) |
Lokalisation |
Nucleus, Cytoplasm, Cell Membrane |
LMO2
|
Zeta Corporation |
ZR87 |
1 ml |
Concentrate |
CE/IVD |
Z2397RL |
-
|
Host |
Rabbit |
Klon |
ZR87 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Lymph Node |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Recombinant human LMO2 protein fragment (around aa 23-140) |
Lokalisation |
Nucleus, Cytoplasm, Cell Membrane |
LMO2
|
Zeta Corporation |
ZR87 |
7 ml |
Concentrate |
CE/IVD |
Z2397RP |
-
|
Host |
Rabbit |
Klon |
ZR87 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Lymph Node |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant human LMO2 protein fragment (around aa 23-140) |
Lokalisation |
Nucleus, Cytoplasm, Cell Membrane |
LMO2
|
Zeta Corporation |
ZR87 |
0.5 ml |
Concentrate |
CE/IVD |
Z2397RS |
-
|
Host |
Rabbit |
Klon |
ZR87 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Lymph Node |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant human LMO2 protein fragment (around aa 23-140) |
Lokalisation |
Nucleus, Cytoplasm, Cell Membrane |
LMO2
|
Zeta Corporation |
ZR87 |
0.1 ml |
Concentrate |
CE/IVD |
Z2397RT |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Lysozyme
|
Diagnostic Biosystems |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PDR005 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Lysozyme
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP028 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Lysozyme
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP028-01 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Lysozyme
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP028-05 |
-
|
Host |
Monospecific Mouse |
Klon |
ZM120 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Myeloid leukemia |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant fragment of human Lysozyme protein (around aa 18-147) |
Lokalisation |
Cytoplasm |
Lysozyme
|
Zeta Corporation |
ZM120 |
1 ml |
Concentrate |
CE/IVD |
Z2425ML |
-
|